3 research outputs found
Prevalence and characteristics of community carriage of methicillin-resistant Staphylococcus aureus in Malta
Methicillin-resistant Staphylococcus aureus (MRSA) is a major nosocomial pathogen worldwide. Malta is one of the countries with the highest MRSA prevalence in Europe, as identified from hospital blood cultures [1]. However, community prevalence of MRSA has never previously been investigated. This study aimed at establishing the prevalence of community MRSA nasal colonization in Maltese individuals and identifying the clonal characteristics of the detected isolates. Nasal swabs were collected from 329 healthy individuals who were also asked to complete a brief questionnaire about risk factors commonly associated with MRSA carriage and infection. The swabs were transported and enriched in a nutrient broth supplemented with NaCl. The presence of MRSA was then determined by culturing on MRSA Select chromogenic agar and then confirming by several assays, including catalase, coagulase and PBP2a agglutination tests. The isolates were assayed for antibiotic susceptibilities and typed by micro-array analysis to determine the clonal characteristics of each strain. The prevalence of MRSA nasal colonization in the healthy Maltese population was found to be 8.81% (95% confidence interval [CI], 5.75–11.87%), much higher than that found in other studies carried out in several countries. No statistical association was found between MRSA carriage and demographics or risk factors; however, this was hindered by the small sample size. Almost all the isolates were fusidic-acid resistant. The majority were found to belong to a local endemic clone (CC5) which seems to be replacing the previously prevalent European clone UK-EMRSA-15 in the country. A new clone (CC50-MRSA-V) was also characterized. The presence of such a significant community reservoir of MRSA increases the burdens already faced by the local healthcare system to control the MRSA epidemic. Colonization of MRSA in otherwise healthy individuals may represent a risk for endogenous infection and transmission to hospitalized patients after admission to a healthcare facility, leading to longer hospital stays and, consequently, increased healthcare costs.peer-reviewe
PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer
Protein expression, activation and stability are regulated through inter-connected signal transduction pathways resulting in specific cellular states.
This study sought to differentiate between the complex mechanisms of
intrinsic and acquired trastuzumab resistance, by quantifying changes in
expression and activity of proteins (phospho-protein profile) in key signal
transduction pathways, in breast cancer cellular models of trastuzumab
resistance. To this effect, we utilized a multiplex, bead-based protein assay,
DigiWest®, to measure around 100 proteins and protein modifications using
specific antibodies. The main advantage of this methodology is the
quantification of multiple analytes in one sample, utilising input volumes of a
normal western blot. The intrinsically trastuzumab-resistant cell line JIMT-1
showed the largest number of concurrent resistance mechanisms, including
PI3K/Akt and RAS/RAF/MEK/ERK activation, b catenin stabilization by inhibitory
phosphorylation of GSK3b, cell cycle progression by Rb suppression, and
CREB-mediated cell survival. MAPK (ERK) pathway activation was common to
both intrinsic and acquired resistance cellular models. The overexpression of
upstream RAS/RAF, however, was confined to JIMT 1; meanwhile, in a cellular
model of acquired trastuzumab resistance generated in this study (T15), entry
into the ERK pathway seemed to be mostly mediated by PKCa activation. This is
a novel observation and merits further investigation that can lead to new
therapeutic combinations in HER2-positive breast cancer with acquired
therapeutic resistance.peer-reviewe
Network and systems medicine: Position paper of the European Collaboration on Science and Technology action on Open Multiscale Systems Medicine
Introduction: Network and systems medicine has rapidly evolved over the past decade, thanks to computational and integrative tools, which stem in part from systems biology. However, major challenges and hurdles are still present regarding validation and translation into clinical application and decision making for precision medicine.
Methods: In this context, the Collaboration on Science and Technology Action on Open Multiscale Systems Medicine (OpenMultiMed) reviewed the available advanced technologies for multidimensional data generation and integration in an open-science approach as well as key clinical applications of network and systems medicine and the main issues and opportunities for the future.
Results: The development of multi-omic approaches as well as new digital tools provides a unique opportunity to explore complex biological systems and networks at different scales. Moreover, the application of findable, applicable, interoperable, and reusable principles and the adoption of standards increases data availability and sharing for multiscale integration and interpretation. These innovations have led to the first clinical applications of network and systems medicine, particularly in the field of personalized therapy and drug dosing. Enlarging network and systems medicine application would now imply to increase patient engagement and health care providers as well as to educate the novel generations of medical doctors and biomedical researchers to shift the current organ- and symptom-based medical concepts toward network- and systems-based ones for more precise diagnoses, interventions, and ideally prevention.
Conclusion: In this dynamic setting, the health care system will also have to evolve, if not revolutionize, in terms of organization and management